Analysis from top brokerages on Bangkok Dusit Medical Services Public Company Limited (SET: BDMS) pointed to firmer operating momentum in the third quarter of 2026, led by domestic patient demand and better hospital utilization. DBS and Morgan Stanley retained positive calls on the stock after results came broadly in line with forecasts, while HSBC highlighted early signs of recovery.
DBS said BDMS delivered core profit of THB 4.51 billion for the quarter, up 4% from a year earlier and 42% from the previous quarter. The figure was consistent with both its estimates and market expectations. The broker kept its “Buy” rating and a discounted cash flow-based target price of THB 23.
The earnings performance was supported by Thai patient revenue, which DBS said increased 7% year-on-year and helped counter weaker overseas demand. DBS expects fourth-quarter earnings to improve from the same period last year but ease from the third quarter. It cited growth in the insurance segment, a low comparison base for Cambodian revenue and the absence of THB 416 million in one-off costs booked in 4Q25.
Morgan Stanley maintained an “Overweight” rating with a target price of THB 25.50. It said BDMS revenue rose 6.6% YoY in the third quarter, while EBITDA and PATMI advanced 8% and 5%, respectively. Revenue and profit were less than 1% below consensus estimates.
Thai patient revenue rose 7% from a year earlier and 14% quarter-on-quarter, helped by seasonal illnesses and higher-complexity treatments. Morgan Stanley noted that Bumrungrad Hospital PCL (SET: BH)’s Thai revenue increased 8% YoY, supported by stronger inpatient admissions and higher treatment intensity.
International revenue at BDMS increased 4% YoY and 9% QoQ, with growth from the U.S., Myanmar and the UAE. Excluding Cambodia and the Middle East, international revenue rose 11%, while hospital revenue grew 8%. EBITDA margin improved 20 basis points to 25.4% as occupancy reached 67%, compared with 66% in 3Q25 and 55% in 2Q26.
HSBC said the third-quarter results showed an emerging recovery trend, with Thai patients, higher occupancy and improved EBITDA margin supporting the performance.





